Security
Nuvalent, Inc. Class A Common Stock · NUVL
NUVLNASDAQCommon stockHistorical · closed Jul 15, 2026CIK 1861560Updated Oct 6, 2026
NUVL price & chart
Historical security
This listing closed Jul 15, 2026. Live provider charts are shown only for current listings.
About the company
Nuvalent (NASDAQ: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, Nuvalent develops innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
In the news
Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders ↗
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Nuvalent, Inc. (NASDAQ: NUVL) ↗
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders News provided by Nuvalent, Inc. Nov 24, 2025, 16:01 ET Share this article Share to X Share this article Share to X CAMBRIDGE, Mass. , Nov. ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 979,910,000Source | 1,188,858,000Source | 425,080,000Source | 1,040,543,000Source | 675,230,000Source | 1,331,148,000Source | 1,105,806,000Source | 708,466,000Source | 1,412,705,000Source | 1,141,752,000Source | 732,384,000Source | 482,459,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 115,752,000Source | 369,244,000Source | 88,434,000Source | 127,470,000Source | 77,700,000Source | 159,733,000Source | 120,835,000Source | 98,515,000Source | 261,745,000Source | 145,691,000Source | 335,387,000Source | 241,806,000Source |
| Assets, CurrentUSD | 956,945,000Source | 1,179,675,000Source | 419,773,000Source | 1,019,610,000Source | 666,258,000Source | 1,307,937,000Source | 1,086,553,000Source | 699,494,000Source | 1,392,426,000Source | 1,132,448,000Source | 726,488,000Source | 477,991,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 13,842,000Source | 11,366,000Source | 6,515,000Source | 14,012,000Source | 8,264,000Source | 20,461,000Source | 13,328,000Source | 7,657,000Source | 20,474,000Source | 14,146,000Source | 6,583,000Source | 5,828,000Source |
| Other Assets, NoncurrentUSD | 22,965,000Source | 9,183,000Source | 5,307,000Source | 20,933,000Source | 8,972,000Source | 23,211,000Source | 19,253,000Source | 8,972,000Source | 20,279,000Source | 9,304,000Source | 5,896,000Source | 4,468,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 134,511,000Source | 67,732,000Source | 29,103,000Source | 100,801,000Source | 38,192,000Source | 156,781,000Source | 94,749,000Source | 33,427,000Source | 164,366,000Source | 71,960,000Source | 31,823,000Source | 19,481,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | 0Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -853,724,000Source | -472,289,000Source | -248,004,000Source | -731,287,000Source | -387,944,000Source | -1,081,708,000Source | -631,634,000Source | -330,778,000Source | -972,429,000Source | -547,052,000Source | -286,296,000Source | -160,077,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 2,370,000Source | 1,373,000Source | -1,310,000Source | 1,363,000Source | -1,571,000Source | -1,355,000Source | 854,000Source | -1,318,000Source | 2,353,000Source | -59,000Source | 31,000Source | -494,000Source |
| Stockholders' Equity Attributable to ParentUSD | 845,399,000Source | 1,121,126,000Source | 395,977,000Source | 939,742,000Source | 637,038,000Source | 1,174,367,000Source | 1,011,057,000Source | 675,039,000Source | 1,248,339,000Source | 1,069,792,000Source | 700,561,000Source | 462,978,000Source |
| Additional Paid in Capital, Common StockUSD | 1,696,745,000Source | 1,592,034,000Source | 645,285,000Source | 1,669,658,000Source | 1,026,546,000Source | 2,257,422,000Source | 1,641,829,000Source | 1,007,128,000Source | 2,218,407,000Source | 1,616,895,000Source | 986,819,000Source | 623,543,000Source |
| Liabilities and EquityUSD | 979,910,000Source | 1,188,858,000Source | 425,080,000Source | 1,040,543,000Source | 675,230,000Source | 1,331,148,000Source | 1,105,806,000Source | 708,466,000Source | 1,412,705,000Source | 1,141,752,000Source | 732,384,000Source | 482,459,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 89,151,000Source | 51,132,000Source | 29,103,000Source | 75,147,000Source | 38,192,000Source | 81,051,000Source | 75,034,000Source | 33,427,000Source | 91,171,000Source | 54,020,000Source | 31,823,000Source | 19,481,000Source |
| Accounts Payable, CurrentUSD | 22,010,000Source | 15,934,000Source | 9,781,000Source | 13,342,000Source | 7,403,000Source | 22,136,000Source | 26,165,000Source | 13,396,000Source | 30,158,000Source | 5,225,000Source | 9,274,000Source | 7,195,000Source |
| Other Liabilities, NoncurrentUSD | 140,000Source | — | — | 244,000Source | — | 0Source | 345,000Source | — | 35,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | 35,198,000Source | 19,322,000Source | — | 30,789,000Source | — | — | 20,031,000Source | — | 48,795,000Source | 22,549,000Source | 12,286,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | 0Source | — | 5,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -109,279,000Source | -84,582,000Source | -425,377,000Source | -260,756,000Source | -126,219,000Source | -81,854,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 28,880,000Source | 20,380,000Source | 86,502,000Source | 60,579,000Source | 25,563,000Source | 10,325,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -7,688,000Source | 20,940,000Source | 24,599,000Source | -4,049,000Source | 2,169,000Source | 4,212,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -92,399,000Source | -54,821,000Source | -275,209,000Source | -185,064,000Source | -99,739,000Source | -64,971,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -19,414,000Source | 25,417,000Source | -124,077,000Source | -573,514,000Source | -143,527,000Source | -10,665,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 9,801,000Source | 4,548,000Source | 515,340,000Source | 568,882,000Source | 336,847,000Source | 248,916,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -102,012,000Source | -24,856,000Source | 116,054,000Source | -189,696,000Source | 93,581,000Source | 173,280,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 115,752,000Source | 369,244,000Source | 127,470,000Source | 77,700,000Source | 159,733,000Source | 120,835,000Source | 261,745,000Source | 145,691,000Source | 335,387,000Source | 241,806,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 22,314,000Source | 15,459,000Source | 22,074,000Source | 15,125,000Source | 28,880,000Source | 20,380,000Source | 86,502,000Source | 60,579,000Source | 25,563,000Source | 10,325,000Source |
| General and Administrative ExpenseUSD | — | — | 28,853,000Source | 15,780,000Source | 23,658,000Source | 15,984,000Source | 35,799,000Source | 20,394,000Source | 107,337,000Source | 62,594,000Source | 36,249,000Source | 22,377,000Source |
| Income Tax Expense (Benefit)USD | — | — | 132,000Source | 40,000Source | 145,000Source | 170,000Source | 168,000Source | 157,000Source | 585,000Source | 764,000Source | — | — |
| Investment Income, InterestUSD | — | — | 10,203,000Source | 8,652,000Source | 11,118,000Source | 8,150,000Source | 12,862,000Source | 11,835,000Source | 44,794,000Source | 38,372,000Source | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | 1,007,000Source | 2,944,000Source | 509,000Source | -253,000Source | -3,708,000Source | 913,000Source | 2,412,000Source | -90,000Source | 525,000Source | -266,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -122,437,000Source | -84,345,000Source | -99,653,000Source | -57,166,000Source | -109,279,000Source | -84,582,000Source | -425,377,000Source | -260,756,000Source | -126,219,000Source | -81,854,000Source |
| Nonoperating Income (Expense)USD | — | — | -9,609,000Source | -7,974,000Source | 5,063,000Source | 8,154,000Source | 10,296,000Source | 10,387,000Source | -10,485,000Source | 20,376,000Source | 23,273,000Source | 4,254,000Source |
| Operating ExpensesUSD | — | — | 112,696,000Source | 76,331,000Source | 104,571,000Source | 65,150,000Source | 119,407,000Source | 94,812,000Source | 414,307,000Source | 280,368,000Source | 149,492,000Source | 86,108,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 10,135,000Source | 4,554,000Source | 515,722,000Source | 569,987,000Source | 324,300,000Source | 248,630,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | 13,793,000Source | 1,840,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -112,696,000Source | -76,331,000Source | -104,571,000Source | -65,150,000Source | -119,407,000Source | -94,812,000Source | -414,307,000Source | -280,368,000Source | -149,492,000Source | -86,108,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -122,305,000Source | -84,305,000Source | -99,508,000Source | -56,996,000Source | -109,111,000Source | -84,425,000Source | -424,792,000Source | -259,992,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | 132,000Source | 40,000Source | 145,000Source | 170,000Source | 168,000Source | 157,000Source | 585,000Source | 764,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -122,437,000Source | -84,345,000Source | -99,653,000Source | -57,166,000Source | -109,279,000Source | -84,582,000Source | -425,377,000Source | -260,756,000Source | -126,219,000Source | -81,854,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.7Source | -1.28Source | -1.39Source | -0.88Source | -1.39Source | -1.18Source | -5.85Source | -3.93Source | -2.17Source | -1.65Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.7Source | -1.28Source | -1.39Source | -0.88Source | -1.39Source | -1.18Source | -5.85Source | -3.93Source | -2.17Source | -1.65Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 72,143,466Source | 65,678,693Source | 71,843,774Source | 64,605,308Source | 78,670,371Source | 71,607,546Source | 72,686,749Source | 66,408,807Source | 58,223,339Source | 49,668,864Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 72,143,466Source | 65,678,693Source | 71,843,774Source | 64,605,308Source | 78,670,371Source | 71,607,546Source | 72,686,749Source | 66,408,807Source | 58,223,339Source | 49,668,864Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 28,853,000Source | 15,780,000Source | 23,658,000Source | 15,984,000Source | 35,799,000Source | 20,394,000Source | 107,337,000Source | 62,594,000Source | 36,249,000Source | 22,377,000Source |
| Interest and Other IncomeUSD | — | — | — | — | — | — | — | — | — | — | — | 4,254,000Source |
| Investment Income, InterestUSD | — | — | 10,203,000Source | 8,652,000Source | 11,118,000Source | 8,150,000Source | 12,862,000Source | 11,835,000Source | 44,794,000Source | 38,372,000Source | — | — |
| Labor and Related ExpenseUSD | — | — | 41,041,000Source | 26,193,000Source | 38,765,000Source | 25,066,000Source | 23,590,000Source | 14,928,000Source | 73,163,000Source | 104,700,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | -9,609,000Source | -7,974,000Source | 5,063,000Source | 8,154,000Source | 10,296,000Source | 10,387,000Source | -10,485,000Source | 20,376,000Source | 23,273,000Source | 4,254,000Source |
| Operating ExpensesUSD | — | — | 112,696,000Source | 76,331,000Source | 104,571,000Source | 65,150,000Source | 119,407,000Source | 94,812,000Source | 414,307,000Source | 280,368,000Source | 149,492,000Source | 86,108,000Source |
| Research and Development ExpenseUSD | — | — | 83,843,000Source | 60,551,000Source | 80,913,000Source | 49,166,000Source | 83,608,000Source | 74,418,000Source | 306,970,000Source | 217,774,000Source | 113,243,000Source | 63,731,000Source |
| Interest Income (Expense), Net | — | — | — | —Source | — | —Source | — | — | — | — | — | — |
Filing attachments
d130887dex991.htm · SC14D9C · 2026-06-09
Exhibit 99.1 Nuvalent Transaction All-Employee Note To: All Nuvalent Employees From: James Porter Subject: An Exciting New Chapter Date: June 9, 2026 Hello Team, Earlier this morning, we announced that Nuvalent has agreed to be acquired by GSK. This transaction is a landmark achievement for our company that will help realize the full potential of our pipeline and make a meaningful difference in the lives of patients living with cancer. You can read our press release on the announcement he…
Read attachment ↗d130887dex992.htm · SC14D9C · 2026-06-09
Exhibit 99.2 Nuvalent Transaction Employee FAQ Why is GSK acquiring Nuvalent? Why now? ─────────────────────────────────────────── This team has generated a tremendous amount of positive momentum across all aspects of our business. Nuvalent is an attractive opportunity that is anchored by two potential best-in-class lung programs with positive pivotal data and clear near-term paths to first FDA approvals, and followed by an innovative early stage clinical and discovery portfolio. …
Read attachment ↗d137459dex991.htm · 8-K · 2026-06-09
EX-99.1 4 d137459dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Stock-exchange announcement For media and investors only ─────────────────────────────── Issued: 9 June 2026, London UK GSK enters agreement to acquire Nuvalent, Inc. Multi-product oncology deal for assets that have validated targets and aim to address efficacy and/or tolerability limitations of existing therapies Includes two late-stage, potential best-in-class ROS1 (zidesamtinib) and ALK (neladalkib) inhibitors f…
Read attachment ↗nuvl-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 nuvl-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review with PDUFA target action date of September 18, 2026 Submission for potential label expansion of zidesamtinib in TKI-naïve advanced ROS1-posi…
Read attachment ↗nuvl-ex99_1.htm · 8-K · 2026-02-26
EX-99.1 2 nuvl-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review; PDUFA target action date of September 18, 2026 NDA submission for neladalkib in TKI pre-treated advanced ALK-positive NSCLC…
Read attachment ↗nuvl-ex99_1.htm · 8-K · 2026-01-14
Exhibit 99.1 Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026 NDA submission for neladalkib in TKI pre-treated advanced ALK-positive NSCLC population planned for the first half of 2026 Submission for potential indication expansion of zidesamtinib in TKI-naïve advanced ROS1-positiv…
Read attachment ↗